Intro Pullout Text Widget

RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

New Editor-in-Chief: Professor Gerd Burmester

BMJ and EULAR are delighted to announce that Professor Gerd Burmester has been appointed as the new Editor-in-Chief for RMD Open.

Professor Burmester was the Director of the Department of Rheumatology and Clinical Immunology at the Charité Universitätsmedizin Berlin until very recently and is now a Senior Professor at this institution. He is a former President of EULAR. Since 2017 he has been President of the Board of Trustees of the FOREUM Foundation for Research in Rheumatology.

Professor Burmester has been an active supporter of RMD Open since its inception and we're excited that he has agreed to take the journal forward into its next stage of development.

Intro Pullout Text Widget

RMD Open

New Editor-in-Chief: Professor Gerd Burmester

Latest Articles

Vasculitis:

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register

Spondyloarthritis:

Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry

Rheumatoid arthritis:

Predictors of perceived risk in first-degree relatives of patients with rheumatoid arthritis

Autoimmunity:

Interferon signature in systemic autoimmune diseases: what does it mean?

Sjögren syndrome:

Dysregulated long non-coding RNA in Sjögren’s disease impacts both interferon and adaptive immune responses

Why submit to RMD Open?

RMD Open

Most Read Articles

Rheumatoid arthritis:

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

Miscellaneous:

Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

Miscellaneous:

Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs

Systemic sclerosis:

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort

Lupus:

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial

COVID-19 Content

INFLAMMATORY ARTHRITIS:

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

RHEUMATOID ARTHRITIS:

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

INFECTIONS:

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination

INFECTIONS:

Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis

INFECTIONS:

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity